Search

Your search keyword '"Enblad, G"' showing total 402 results
Start Over Author "Enblad, G"
402 results on '"Enblad, G"'

2. SOLUBLE MACROPHAGE MARKER SCD163 PREDICTS OUTCOME IN BOTH CHEMOIMMUNOTHERAPY AND TARGETED THERAPY TREATED MANTLE CELL LYMPHOMA

Author

Nikkarinen, A., primary, Lokhande, L., additional, Amini, R., additional, Jerkeman, M., additional, Porwit, A., additional, Molin, D., additional, Enblad, G., additional, Kolstad, A., additional, Räty, R., additional, Hutchings, M., additional, Weibull, C. E., additional, Hollander, P., additional, Ek, S., additional, and Glimelius, I., additional

Published
2023
Full Text
View/download PDF

7. 1644P PSA trajectories and prediction of time to no-longer clinically benefitting in metastatic castration-resistant prostate cancer: Insights from the ProBio trial

Author

Broer, L., Oldenburg, J., Mortezavi, A., Lindberg, J., Discacciati, A., Karlsson, C.T., Ullén, A., Jänes, E., Enblad, G., Pettersson, L., Vigmostad, M.N., Hjälm-Eriksson, M.E., Olsson, M., Schatteman, P., Ghysel, C., De Laere, B., Grönberg, H., Ost, P., Eklund, M., and Crippa, A.

Published
2024
Full Text
View/download PDF

8. 1636P Health-related quality of life outcomes of androgen receptor pathway inhibitors versus taxanes versus standard of care in metastatic castration-resistant prostate cancer: Results from the ProBio trial

Author

Bultijnck, R., Strijbos, M.H., Mortezavi, A., Lindberg, J., Discacciati, A., Karlsson, C.T., Ullén, A., Jänes, E., Enblad, G., Oldenburg, J., Sautois, B., Hjälm-Eriksson, M.E., Sagstuen Haugnes, H., Schatteman, P., Ghysel, C., De Laere, B., Eklund, M., Grönberg, H., Ost, P., and Crippa, A.

Published
2024
Full Text
View/download PDF

10. 1619P Efficacy of carboplatin in patients with metastatic castration-resistant prostate cancer: Results from the biomarker-driven, randomised, outcome-adaptive ProBio trial

Author

Kristiansen, A., Sautois, B., Crippa, A., Mortezavi, A., Discacciati, A., Karlsson, C.T., Ullén, A., Jänes, E., Enblad, G., Oldenburg, J., Sandzén, J., Vigmostad, M.N., Hjälm-Eriksson, M.E., De Laere, B., Strijbos, M.H., Ghysel, C., Lindberg, J., Eklund, M., Ost, P., and Grönberg, H.

Published
2024
Full Text
View/download PDF

11. Prognostic relevance of pre-treatment c-reactive protein to albumin ratio in patients with diffuse large b cell lymphoma

Author

Nicolaescu, T-M, Abu Sabaa, A., Hedell, K., Morth, C., Valachis, Antonis, Enblad, G., Nicolaescu, T-M, Abu Sabaa, A., Hedell, K., Morth, C., Valachis, Antonis, and Enblad, G.

Abstract

Background: Previous studies have shown that a high level of pre-treatment C-reactive protein to albumin ratio (CAR) is associated with poor outcomes in patients with diffuse large B cell lymphoma (DLBCL). However, these were single-centre studies with a relatively small number of patients. The aim of our study was to further investigate the prognostic value of CAR in a larger cohort and whether the addition of CAR to the International Prognostic Index (IPI) would result in a better discriminatory ability. Methods: All adult patients treated 2000–2013 with R-CHOP/CHOP-like treatment for DLBCL in four counties of Sweden were included (n=414). The study population was divided into high respectively low CAR group using the Budczies et al.’s cut-off finder. The groups were compared in terms of differences in clinical characteristics, response to treatment and survival. The prognostic ability of IPI vs IPI plus CAR was compared by receiver-operating-characteristic curve (ROC), net reclassification improvement (NRI) and the integrated discrimination improvement index (IDI). Results: The high CAR group was associated with higher IPI score, lower performance status, high LDH, bulky disease and more advanced Ann Arbour stage. The high CAR group had a higher proportion of patients with progressive disease (24.2% vs 6.4%, p<0.001) and a lower proportion of patients with complete remission (61.5% vs 85.7%, p<0.01). The high CAR group had poorer 5-year OS (49% vs 70%; p<0.001) and EFS (45% vs 68%; p<0.001). After adjustment for BMI, bulky disease and IPI, high CAR values independently predicted poor OS (HR: 1.58, 95% CI 1.18–2.11; p=0.002) and EFS (HR: 1.57, 95% CI 1.18–2.10; p=0.002). When assessed by NRI, the addition of CAR to IPI seems to better identify patients with better prognosis compared with IPI alone. However, the area under the ROC curve and IDI did not show any significant improvement in model performance. Conclusions: CAR seems to be a useful prognosti

Published
2022
Full Text
View/download PDF

15. LBA86 Androgen receptor pathway inhibitors or taxanes for patients with metastatic castration-resistant prostate cancer: A direct comparison in ProBio, a randomized, outcome-adaptive, biomarker-driven platform trial

Author

Grönberg, H., Lindberg, J., De Laere, B., Crippa, A., Discacciati, A., Karlsson, C.T., Ullén, A., Jänes, E., Mortezavi, A., Ost, P., Enblad, G., Oldenburg, J., Sandzén, J., Pettersson, L., Vigmostad, M.N., Hjälm-Eriksson, M.E., Olsson, M., Schatteman, P., Ghysel, C., and Eklund, M.

Published
2023
Full Text
View/download PDF

16. PLASMA PROTEIN PROFILING USING MULTIPLEX EXTENSION ASSAY IN DLBCL. A DESCRIPTIVE STUDY EXPLORING PLASMA PROTEIN PATTERN EVOLUTION IN DLBCL TREATED WITH R‐CHOP.

Author

Sabaa, A. H. Abu, Mörth, C., Molin, D., Freyhult, E., Kamali‐Moghaddam, M., Eriksson, A., and Enblad, G.

Subjects
BLOOD proteins, ANTINEOPLASTIC combined chemotherapy protocols, PLASMA products, CYCLIN-dependent kinase inhibitors
Abstract

B Background: b In a previous study utilizing multiplex protein extension assay (PEA) we were able to highlight significant differences in pretreatment plasma proteins in lymphoma and leukemia patients compared to age and gender matched controls. PLASMA PROTEIN PROFILING USING MULTIPLEX EXTENSION ASSAY IN DLBCL. A DESCRIPTIVE STUDY EXPLORING PLASMA PROTEIN PATTERN EVOLUTION IN DLBCL TREATED WITH R-CHOP. [Extracted from the article]

Published
2023
Full Text
View/download PDF

28. Relationship between age and survival in cancer of the colon and rectum with special reference to patients less than 40 years of age

Author

Enblad, G., Enblad, P., Adami, H.O., Glimelius, B., Krusemo, U., and Pahlman, L.

Subjects
Sweden -- Health aspects, Adenocarcinoma -- Patient outcomes, Adenocarcinoma -- Statistics, Colorectal cancer -- Demographic aspects, Colorectal cancer -- Patient outcomes, Health
Abstract

Cancer of the colon or rectum (colorectal cancer) in patients under the age of 40 is uncommon, and the prognosis for these patients is controversial. All individuals (61,769) in Sweden with malignant tumor of the colon and rectum, reported between 1960 and 1981, were analyzed. These patients had national registration numbers and almost complete follow-up was obtained, permitting life tables and relative survival rates to be calculated. The results of this analysis indicate that patients below the age of 40 with colorectal cancer have the same or better outcome as older patients. The five-year survival rate for any type of colon cancer was 62 percent in the under 40 group, and 44.4 percent in the older group. However, there were differences in the anatomical location and the type of cancer between the age groups. Younger patients had a higher proportion of carcinoma of the appendix, cecum, and ascending colon; older patients showed a higher proportion of sigmoid and rectal cancer. Carcinoids of the colon were much more frequent in the younger group. A relative survival rate was calculated separately for patients with adenocarcinoma. The five-year survival rate for adenocarcinoma of the colon was 50.9 percent for the under 40 group, and 48.6 percent for the older group; five-year survival for the adenocarcinoma of the rectum was 41.1 percent for the younger group, and 40.7 percent for the older group. (Consumer Summary produced by Reliance Medical Information, Inc.)

Published
1990

29. Six cycles of R-CHOP-21 are not inferior to eight cycles for treatment of diffuse large B-cell lymphoma: a Nordic Lymphoma Group Population-based Study

Author

Wästerlid, T., primary, Biccler, J.L., additional, Brown, P.N., additional, Bøgsted, M., additional, Enblad, G., additional, Mészáros Jørgensen, J., additional, Christensen, J.H., additional, Wahlin, B.E., additional, Smedby, K.E., additional, El-Galaly, T.C., additional, and Jerkeman, M., additional

Published
2018
Full Text
View/download PDF

30. Six cycles of R-CHOP-21 are not inferior to eight cycles for treatment of diffuse large B-cell lymphoma:a Nordic Lymphoma Group Population-based Study

Author

Wästerlid, T, Biccler, J L, Brown, P N, Bøgsted, M, Enblad, G, Mészáros Jørgensen, J, Christensen, J H, Wahlin, B E, Smedby, K E, El-Galaly, T C, Jerkeman, M, Wästerlid, T, Biccler, J L, Brown, P N, Bøgsted, M, Enblad, G, Mészáros Jørgensen, J, Christensen, J H, Wahlin, B E, Smedby, K E, El-Galaly, T C, and Jerkeman, M

Published
2018

32. Frequent NFKBIE deletions are associated with poor outcome in primary mediastinal B-cell lymphoma

Author

Mansouri, L. Noerenberg, D. Young, E. Mylonas, E. Abdulla, M. Frick, M. Asmar, F. Ljungström, V. Schneider, M. Yoshida, K. Skaftason, A. Pandzic, T. Gonzalez, B. Tasidou, A. Waldhueter, N. Rivas-Delgado, A. Angelopoulou, M. Ziepert, M. Arends, C.M. Couronné, L. Lenze, D. Baldus, C.D. Bastard, C. Okosun, J. Fitzgibbon, J. Dörken, B. Drexler, H.G. Roos-Weil, D. Schmitt, C.A. Munch-Petersen, H.D. Zenz, T. Hansmann, M.-L. Strefford, J.C. Enblad, G. Bernard, O.A. Ralfkiaer, E. Erlanson, M. Korkolopoulou, P. Hultdin, M. Papadaki, T. Grønbæk, K. Lopez-Guillermo, A. Ogawa, S. Küppers, R. Stamatopoulos, K. Stavroyianni, N. Kanellis, G. Rosenwald, A. Campo, E. Amini, R.-M. Ott, G. Vassilakopoulos, T.P. Hummel, M. Rosenquist, R. Damm, F.

Subjects
hemic and lymphatic diseases
Abstract

We recently reported a truncating deletion in the NFKBIE gene, which encodes IκB, a negative feedback regulator of NF-κB, in clinically aggressive chronic lymphocytic leukemia (CLL). Because preliminary data indicate enrichment of NFKBIE aberrations in other lymphoid malignancies, we screened a large patient cohort (n 5 1460) diagnosed with different lymphoid neoplasms. While NFKBIE deletions were infrequent in follicular lymphoma, splenic marginal zone lymphoma, and T-cell acute lymphoblastic leukemia (

Published
2016

34. A PHASE 1/2 STUDY OF PIXANTRONE, ETOPOSIDE, BENDAMUSTINE AND, IN CD20+ TUMORS, RITUXIMAB IN PATIENTS WITH RELAPSED AGGRESSIVE B- OR T-CELL LYMPHOMAS-THE P[R]EBEN STUDY

Author

d'Amore, F., primary, Leppä, S., additional, Larsen, T.S., additional, Brown, P., additional, Relander, T., additional, Mannisto, S., additional, Jørgensen, J.M., additional, Holte, H., additional, Lauritzsen, G.F., additional, Enblad, G., additional, and Toldbod, H., additional

Published
2017
Full Text
View/download PDF

35. RESPONSE-ADJUSTED THERAPY FOR ADVANCED HODGKIN LYMPHOMA (RATHL) TRIAL: LONGER FOLLOW UP CONFIRMS EFFICACY OF DE-ESCALATION AFTER a NEGATIVE INTERIM PET SCAN (CRUK/07/033).

Author

Trotman, J., primary, Fosså, A., additional, Federico, M., additional, Stevens, L., additional, Kirkwood, A., additional, Clifton-Hadley, L., additional, Patrick, P., additional, Berkahn, L., additional, D'Amore, F., additional, Enblad, G., additional, Luminari, S., additional, Radford, J., additional, Barrington, S.F., additional, and Johnson, P., additional

Published
2017
Full Text
View/download PDF

36. APPLICATION OF a GENE EXPRESSION-BASED MODEL IN COMBINATION WITH FDG-PET IMAGING TO PREDICT TREATMENT RESPONSE IN ADVANCED HODGKIN LYMPHOMA IN THE RATHL STUDY (CRUK/07/033)

Author

Burton, C.H., primary, Scott, D., additional, Kirkwood, A.A., additional, Gandhi, M., additional, Radford, J., additional, Barrington, S., additional, Federico, M., additional, Luminari, S., additional, Trotman, J., additional, Berkhan, L., additional, D'Amore, F.A., additional, Kamp, P., additional, Enblad, G., additional, Molin, D., additional, Chalkley, R., additional, Smith, P., additional, Stevens, L., additional, Roberts, T., additional, Patrick, P., additional, Chan, F., additional, Harvey, Y., additional, Mottok, A., additional, Gascoyne, R., additional, and Johnson, P., additional

Published
2017
Full Text
View/download PDF

38. OUTCOMES OF TREATMENT FOR OBESE PATIENTS WITH ADVANCED HODGKIN LYMPHOMA IN THE RATHL TRIAL (CRUK/07/033)

Author

Preston, A., primary, Kirkwood, A., additional, Federico, M., additional, Trotman, J., additional, Fossa, A., additional, Stevens, L., additional, Clifton-Hadley, L., additional, Patrick, P., additional, Berkahn, L., additional, d'Amore, F., additional, Enblad, G., additional, Luminari, S., additional, Radford, J., additional, and Johnson, P.W., additional

Published
2017
Full Text
View/download PDF

40. EXPLORING THE POTENTIAL CORRELATION BETWEEN NEUTROPHIL EXTRACELLULAR TRAPS AND PROGNOSIS IN PATIENTS WITH DIFFUSE LARGE B‐CELL LYMPHOMA AND HODGKIN'S LYMPHOMA.

Author

Pettersson, E., Vemuri, K., Ulfstedt, J. Mattsson, Hedell, K., Berglund, M., Herre, M., Amini, R., Molin, D., Olsson, A., and Enblad, G.

Subjects
DIFFUSE large B-cell lymphomas, LYMPHOMAS, NEUTROPHILS, PROGNOSIS
Abstract

A neutrophil-lymphocyte ratio above 3.0, a known predictor of worse outcome in cancer patients, showed a trend towards being correlated with worse prognosis in DLBCL patients, but this was less evident for HL patients. Here, NETs were measured in plasma from patients with DLBCL and Hodgkin's lymphoma (HL), and correlated to blood counts and clinical outcome of the patients. EXPLORING THE POTENTIAL CORRELATION BETWEEN NEUTROPHIL EXTRACELLULAR TRAPS AND PROGNOSIS IN PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA AND HODGKIN'S LYMPHOMA. [Extracted from the article]

Published
2023
Full Text
View/download PDF

41. Trends in relative survival of Diffuse large B‐cell lymphoma in Sweden in the era of targeted and cellular therapies.

Author

Smedby, K. Ekström, Antonilli, S., Enblad, G., Sonnevi, K., Wahlin, B. E., Andersson, P., Jerkeman, M., and Eloranta, S.

Subjects
DIFFUSE large B-cell lymphomas, CELLULAR therapy, CD19 antigen
Abstract

We speculate that the higher survival rate among young high-risk patients may be driven by the introduction of CAR-T in the last few years, whereas the more general and successive improvement among older patients could be due to intensified treatment schemes in the primary as well as relapsed settings. B Introduction: b Most patients diagnosed with diffuse large B-cell lymphoma (DLBCL) are cured with primary immunochemotherapy, but about one in four experience relapsed/refractory (R/R) disease with worsened outcome. In young high-risk patients, the 2-year RS increased from 71% among patients diagnosed 2007-2009, to 83% among patients diagnosed 2019-2021 ( I p i SB overall sb < 0.001). [Extracted from the article]

Published
2023
Full Text
View/download PDF

42. Genetic and transcriptomic analyses of diffuse large B‐cell lymphoma patients with poor outcomes within two years of diagnosis.

Author

Ren, W., Own, S. A., Wan, H., Berglund, M., Wang, X., Yang, M., Li, X., Liu, D., Sonnevi, K., Enblad, G., Amini, R., Sander, B., Wu, K., Zhang, H., Wahlin, B. E., Smedby, K. E., and Pan‐Hammarström, Q.

Subjects
DIFFUSE large B-cell lymphomas, MOLECULAR diagnosis, TRANSCRIPTOMES
Abstract

We aimed to characterize the molecular features of DLBCL derived from patients with early R/R disease and develop a prognosis model to identify those high-risk patients. B Conclusions: b Our study provides insight into understanding the molecular features of DLBCL with early R/R disease treated with R-CHOP and identifies an 11-gene signature that could help to identify high-risk patients. B Background: b R-CHOP immunochemotherapy is the first-line treatment for DLBCL, but approximately 30%-40% of patients still experience refractory or relapsed (R/R) disease. [Extracted from the article]

Published
2023
Full Text
View/download PDF

43. Functional loss of I kappa B epsilon leads to NF-kappa B deregulation in aggressive chronic lymphocytic leukemia

Author

Mansouri, L, Sutton, LA, Ljungstrom, V, Bondza, S, Arngarden, L, Bhoi, S, Larsson, J, Cortese, D, Kalushkova, A, Plevova, K, Young, E, Gunnarsson, R, Falk-Sorqvist, E, Lonn, P, Muggen, Alice, Yan, XJ, Sander, B, Enblad, G, Smedby, KE, Juliusson, G, Belessi, C, Rung, J, Chiorazzi, N, Strefford, JC, Langerak, Ton, Pospisilova, S, Davi, F, Hellstrom, M, Jernberg-Wiklund, H, Ghia, P, Soderberg, O, Stamatopoulos, K, Nilsson, M, Rosenquist, R, and Immunology

Subjects
hemic and lymphatic diseases
Abstract

NF-kappa B is constitutively activated in chronic lymphocytic leukemia (CLL); however, the implicated molecular mechanisms remain largely unknown. Thus, we performed targeted deep sequencing of 18 core complex genes within the NF-kappa B pathway in a discovery and validation CLL cohort totaling 315 cases. The most frequently mutated gene was NFKBIE (21/315 cases; 7%), which encodes I kappa B epsilon, a negative regulator of NF-kappa B in normal B cells. Strikingly, 13 of these cases carried an identical 4-bp frameshift deletion, resulting in a truncated protein. Screening of an additional 377 CLL cases revealed that NFKBIE aberrations predominated in poor-prognostic patients and were associated with inferior outcome. Minor subclones and/or clonal evolution were also observed, thus potentially linking this recurrent event to disease progression. Compared with wild-type patients, NFKBIE-deleted cases showed reduced I kappa B epsilon protein levels and decreased p65 inhibition, along with increased phosphorylation and nuclear translocation of p65. Considering the central role of B cell receptor (BcR) signaling in CLL pathobiology, it is notable that I kappa B epsilon loss was enriched in aggressive cases with distinctive stereotyped BcR, likely contributing to their poor prognosis, and leading to an altered response to BcR inhibitors. Because NFKBIE deletions were observed in several other B cell lymphomas, our findings suggest a novel common mechanism of NF-kappa B deregulation during lymphomagenesis.

Published
2015

45. Human cytomegalovirus tegument protein pp65 is detected in all intra- and extra-axial brain tumours independent of the tumour type or grade

Author

Libard, S, Popova, SN, Amini, RM, Kärjä, V, Pietiläinen, T, Hämäläinen, KM, Sundström, C, Hesselager, G, Bergqvist, M, Ekman, S, Zetterling, M, Smits, A, Nilsson, P, Pfeifer, S, Diaz de Ståhl, T, Enblad, G, Ponten, F, Alafuzoff, I, Libard, S, Popova, SN, Amini, RM, Kärjä, V, Pietiläinen, T, Hämäläinen, KM, Sundström, C, Hesselager, G, Bergqvist, M, Ekman, S, Zetterling, M, Smits, A, Nilsson, P, Pfeifer, S, Diaz de Ståhl, T, Enblad, G, Ponten, F, and Alafuzoff, I

Published
2016

50. Role of microRNAs and microRNA machinery in the pathogenesis of diffuse large B-cell lymphoma

Author

Caramuta, S., Lee, L., Ozata, D. M., Akcakaya, P., Georgii-Hemming, Patrik, Xie, H., Amini, Rose Marie, Lawrie, C. H., Enblad, G., Larsson, C., Berglund, M., Lui, W-O, Caramuta, S., Lee, L., Ozata, D. M., Akcakaya, P., Georgii-Hemming, Patrik, Xie, H., Amini, Rose Marie, Lawrie, C. H., Enblad, G., Larsson, C., Berglund, M., and Lui, W-O

Abstract

Deregulation of microRNA (miRNA) expression has been documented in diffuse large B-cell lymphoma (DLBCL). However, the impact of miRNAs and their machinery in DLBCL is not fully determined. Here, we assessed the role of miRNA expression and their processing genes in DLBCL development. Using microarray and RT-qPCR approaches, we quantified global miRNAs and core components of miRNA-processing genes expression in 75 DLBCLs (56 de novo and 19 transformed) and 10 lymph nodes (LN). Differential miRNA signatures were identified between DLBCLs and LNs, or between the de novo and transformed DLBCLs. We also identified subsets of miRNAs associated with germinal center B-cell phenotype, BCL6 and IRF4 expression, and clinical staging. In addition, we showed a significant over-expression of TARBP2 in de novo DLBCLs as compared with LNs, and decreased expression of DROSHA, DICER, TARBP2 and PACT in transformed as compared with de novo cases. Interestingly, cases with high TARBP2 and DROSHA expression had a poorer chemotherapy response. We further showed that TARBP2 can regulate miRNA-processing efficiency in DLBCLs, and its expression inhibition decreases cell growth and increases apoptosis in DLBCL cell lines. Our findings provide new insights for the understanding of miRNAs and its machinery in DLBCL.

Published
2013
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results